Yohimbine
| Clinical data | |
|---|---|
| Pronunciation | /joʊˈhɪmbiːn/ |
| Other names | Quebrachine |
| Routes of administration | By mouth |
| Drug class | α2-Adrenergic receptor antagonist |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 7-86% (mean 33%) |
| Elimination half-life | 0.25–2.5 hours |
| Excretion | Urine (as metabolites) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.157 |
| Chemical and physical data | |
| Formula | C21H26N2O3 |
| Molar mass | 354.450 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Yohimbine, also known as quebrachine, is an indole alkaloid derived from the bark of the African tree Pausinystalia johimbe (yohimbe) and from the bark of the unrelated South American tree Aspidosperma quebracho-blanco. It is a veterinary drug used to reverse xylazine.
Substances purported to be extracts from the yohimbe tree have been marketed as dietary supplements for various purposes, especially for erectile dysfunction, but they contain highly variable amounts of yohimbine, if any; no published clinical evidence supports their efficacy for treating sexual dysfunction or any disease.
In the United States, it is illegal to market an over-the-counter (OTC) supplement product containing yohimbine as a treatment for any supposed health effect without having approval from the Food and Drug Administration (FDA). In the United Kingdom, yohimbine is an unlicensed drug, rarely and specifically compounded as a "prescription-only medicine", while yohimbine herbal supplements are banned from manufacturing as dangerous substances.